MedTrace Logo

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

NCT02453555 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2019-02-15

Study results available
· View outcomes & findings →

Summary

This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Linagliptin

DRUG

Empagliflozin placebo + linagliptin placebo low dose

Matching placebo empagliflozin + linagliptin

DRUG

Empagliflozin + linagliptin low dose

tablet

DRUG

Linagliptin placebo

Matching placebo linagliptin

DRUG

Empagliflozin + linagliptin high dose

tablet

DRUG

Empa + lina highdose placebo

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-14
Primary Completion
2016-08-26
Completion
2017-03-27

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453555 on ClinicalTrials.gov